These findings propose THOC2 and THOC5 as novel therapeutic targets for TNBC by eliminating the stem‐like properties of the tumor, and provide molecular insight and rationale to develop the THOC2 or THOC5 inhibitors as targeted treatments for the recurrent TNBC. This evidence concerns the gene THOC2 and neoplasm.